trending Market Intelligence /marketintelligence/en/news-insights/trending/argcp2a-adfs06tezmtqmq2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

Wright Medical's injectable bone graft approved for US market

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Wright Medical's injectable bone graft approved for US market

Wright Medical Group NV's injectable bone graft, named Augment, received premarket approval from the U.S. Food and Drug Administration for use in foot and ankle procedures.

With this decision, the injected formulation can be used for the same procedures as the noninjectable version.

Amsterdam, Netherlands-based Wright Medical will immediately begin finalizing FDA packaging procedures and expects to roll out the product within the next four to six weeks.

Wright projects a $300 million market opportunity in the U.S. for the injectable bone graft, adding in its press release that Augment is the first clinically proven injectable protein therapeutic to come to the U.S. market.